Paul Hudson, Sanofi CEO (Eric Piermont/AFP via Getty Images)
August 17, 2022 06:21 AM EDTUpdated August 19, 04:07 AM
R&D

Up­dat­ed: Hit by an­oth­er PhI­II flop, Sanofi culls breast can­cer drug — sound­ing alarm for the class

Amber Tong

John Carroll

Editor & Founder

Sanofi is of­fi­cial­ly giv­ing up on its oral SERD.

The French drug­mak­er put out word Wednes­day morn­ing that it will

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Some FDA med­ical de­vice staff re­in­stat­ed just days af­ter re­ceiv­ing pink slips

Post-Hoc: Phar­ma CEOs' al­ter­na­tive re­al­i­ty with Trump

Pfiz­er wants in on Sum­mit’s goal to beat Keytru­da via ADC com­bos

Al­con tried to sink Au­ri­on's IPO in 'Valen­tine's Day mas­sacre,' new law­suits say

Pfiz­er hires ex-FDA deputy Pa­trizia Cavaz­zoni as chief med­ical of­fi­cer

sponsored

How AI can ad­dress on­go­ing chal­lenges in the life sci­ences in­dus­try

A service from the Financial Times